Lilly Eli & Co (LLY): Endowment Inc Lilly , 10% owner of Lilly Eli & Co sold 200,000 shares on May 31, 2016. The Insider selling transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were sold at $75.12 per share for a total value of $150232 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, Jackson P Tai (director) purchased 1,080 shares at $75.75 per share price.On May 13, 2016, Endowment Inc Lilly (10% owner) sold 190,000 shares at $76.22 per share price.Also, On May 3, 2016, Donald A Zakrowski (Chief Accounting Officer) sold 1,600 shares at $75.99 per share price.On Apr 28, 2016, Alfonso G Zulueta (SVP& Pres., Emerging Markets) sold 12,000 shares at $76.27 per share price.
Shares of Eli Lilly and Co (LLY) ended Wednesday, Jun 1, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -0.12% at $74.94 with 24,50,242 shares getting traded. Post opening the session at $74.9, the shares hit an intraday low of $74.68 and an intraday high of $75.44 and the price vacillated in this range throughout the day. The company has a market cap of $82,722 M and the number of outstanding shares has been calculated to be 1,10,38,37,000 shares. The 52-week high of Eli Lilly and Co is $92.85 and the 52-week low is $67.88.
Company has been under the radar of several Street Analysts.Eli Lilly and Co is Reiterated by Leerink Partners to Outperform and the brokerage firm has raised the Price Target to $ 101 from a previous price target of $96 .The Rating was issued on May 2, 2016.Eli Lilly and Co is Initiated by Societe Generale to Hold and the brokerage firm has set the Price Target at $78. The Rating was issued on Apr 6, 2016.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.